Leerink calls AC Immune- Eli Lilly Tau amendment ‘great news’

Leerink analyst Marc Goodman says AC Immune’s (ACIU) amendment of the collaboration agreement with Eli Lilly (LLY) for the Morphomer Tau program is “great news” and underscores the continued interest in targeting intracellular Tau as a target for early prevention in Alzheimer’s disease. It also highlights that Lilly hasn’t given up on targeting intracellular Tau after the prior setback with its small molecule OGA inhibitor targeting intracellular Tau, which accelerated the cognitive decline. Additionally, it highlights that pharma remains interested in exploring other modalities than antibody to target Tau in AD, given the recent setbacks with some of the anti Tau mAbs, argues Leerink.